Several such USFDA (U.S. Food and Drug Administration) approved TNF-α antibodies include infliximab, adalizumab, certolizumab, vedolizumab, and golimumab, whereby infliximab was the first product approved for the management of IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.